ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

BACKGROUND: Breakthroughs in oncology have led to the incorporation of immunotherapy to improve the prognosis in patients with advanced malignancies. Checkpoint inhibitors are immunomodulatory antibodies that enhance the immune system using PD-1/PD-L1 and CTLA-4 as primary targets. Pharmacologic dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Cordero, Nicole, Rivera-Nieves, Yadiel, Burgos-Ortega, Nydia, Rosado-Burgos, Alexandra, Ortiz-Rivera, Monica, Madera-Marin, Luis, Gonzalez-Rodriguez, Loida, Alvarado-Santiago, Milliette, Ramirez-Vick, Margarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625745/
http://dx.doi.org/10.1210/jendso/bvac150.1051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625745/
http://dx.doi.org/10.1210/jendso/bvac150.1051

Ejemplares similares